Evidence map›Paper›PMID 41540805›Full record

ArticleNucleic acids research2026

E2F1 K117 methylation by SETD6 disrupts BRD4-E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells.

Gizem Tugce Ulu, Margarita Kublanovsky, Raz Shalev, Tzofit Elbaz Biton, Michal Feldman, Sophia Murr, Jens Brockmeyer, Franziska Dorscht, Sara Weirich, Dan Levy and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gizem Tugce UluInstitute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.
Margarita KublanovskyThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.
Raz ShalevThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.
Tzofit Elbaz BitonThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.
Michal FeldmanThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.
Sophia MurrInstitute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.
Jens BrockmeyerInstitute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.
Franziska DorschtInstitute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.
Sara WeirichInstitute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.
Dan LevyThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, P.O.B. 653, Be'er-Sheva 84105, Israel.ORCID 0000-0003-0719-0305
Albert JeltschInstitute of Biochemistry, University of Stuttgart, Allmandring 31, Stuttgart 70569, Germany.ORCID 0000-0001-6113-9290

Funding

Deutsche Forschungsgemeinschaft JE 252/38-1Israel Cancer AssociationIsrael Science Foundation 496/23
6 · The paper itself

Abstract

The SETD6 (SET domain-containing protein 6) protein lysine methyltransferase regulates various cellular processes including cancer initiation and progression. It monomethylates the transcription factor E2F1 (E2F transcription factor 1) and several other important proteins, but the functional consequences of many SETD6 mediated methylation events are unknown. In this study, the role of SETD6 mediated K117 monomethylation of E2F1 was investigated in prostate cancer cells. In chromatin binding and gene expression experiments, we identified distinct sets of genes that are bound and upregulated by methylated and unmethylated E2F1 indicating that E2F1 methylation by SETD6 directly modulates its chromatin interaction. In agreement with these findings, cellular data showed that E2F1 methylation affects oncogenic phenotypes. Mechanistically, we demonstrate with biochemical, cellular, and genomic assays that SETD6-mediated K117 methylation directly regulates the interaction of E2F1 and BRD4 by preventing K117 acetylation. Our data suggest that K117 methylation/acetylation represents a switch controlling bromodomain binding to E2F1 by which SETD6 methylation regulates different cellular effects of E2F1. Similar mechanisms may apply to the regulation of other transcription factors by SETD6.

Indexed as

ChromatinE2F1 Transcription FactorGene Expression Regulation, NeoplasticHistone-Lysine N-MethyltransferaseNuclear ProteinsProstatic NeoplasmsProtein MethyltransferasesTranscription FactorsAcetylationBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorDNA MethylationHumansLysineMaleBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsChromatinE2F1 protein, humanE2F1 Transcription FactorHistone-Lysine N-MethyltransferaseLysineNuclear ProteinsProtein MethyltransferasesSETD6 protein, humanTranscription Factors

Identifiers

PMID41540805
PMCPMC12808549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.